Explore

Trendline Trendline
Celcuity Faces Investor Backlash Despite Promising Breast Cancer Trial Results

Celcuity Faces Investor Backlash Despite Promising Breast Cancer Trial Results

Celcuity Faces Investor Backlash Despite Promising Breast Cancer Trial Results
Trendline Trendline
Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug

Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug

Celcuity Faces Investor Backlash After Disappointing Trial Results for Breast Cancer Drug
Trendline Trendline
Lupin and Natco Secure U.S. FDA Approval for Eribulin Mesylate Injection, Expanding Cancer Treatment Options

Lupin and Natco Secure U.S. FDA Approval for Eribulin Mesylate Injection, Expanding Cancer Treatment Options

Lupin and Natco Secure U.S. FDA Approval for Eribulin Mesylate Injection, Expanding Cancer Treatment Options
Trendline Trendline
ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial

ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial

ADC Therapeutics Faces Share Price Drop After Patient Deaths in Zynlonta Trial
Trendline Trendline
GE HealthCare's AI-Enabled Radiation Therapy Software Receives FDA Clearance

GE HealthCare's AI-Enabled Radiation Therapy Software Receives FDA Clearance

GE HealthCare's AI-Enabled Radiation Therapy Software Receives FDA Clearance
Trendline Trendline
ADC Therapeutics Faces Investor Concerns Over Cancer Drug Safety Data

ADC Therapeutics Faces Investor Concerns Over Cancer Drug Safety Data

ADC Therapeutics Faces Investor Concerns Over Cancer Drug Safety Data
Trendline Trendline
Ur-Energy Stock Surges Over 20% Following Urenco's Expansion Announcement

Ur-Energy Stock Surges Over 20% Following Urenco's Expansion Announcement

Ur-Energy Stock Surges Over 20% Following Urenco's Expansion Announcement
Trendline Trendline
Major U.S. Markets Hit Record Highs Amid AI Optimism

Major U.S. Markets Hit Record Highs Amid AI Optimism

Major U.S. Markets Hit Record Highs Amid AI Optimism
Trendline Trendline
SpaceX Plans $75 Billion IPO with Fixed Share Price of $135

SpaceX Plans $75 Billion IPO with Fixed Share Price of $135

SpaceX Plans $75 Billion IPO with Fixed Share Price of $135
Trendline Trendline
Xenix Medical Secures FDA Clearance for Riva Posterior Fixation System, Launches Commercially

Xenix Medical Secures FDA Clearance for Riva Posterior Fixation System, Launches Commercially

Xenix Medical Secures FDA Clearance for Riva Posterior Fixation System, Launches Commercially
Reuters Reuters
Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

June 2 (Reuters) - Shares of Fulcrum Therapeutics plunged 50% in premarket trading on Tuesday after the company said it would abandon development of its experimental sickle-cell disease drug following cancer-risk concerns raised by the U.S.
TheStreet TheStreet
Eli Lilly scores a first in major pharma milestone

Eli Lilly scores a first in major pharma milestone

Eli Lilly (LLY) just did something worth paying attention to. With CVS Caremark announcing coverage of both Zepbound and newly approved Foundayo starting this summer, all three of the largest U.S. pharmacy benefit managers now cover Lilly’s complete obesity medicine portfolio. That’s a clean sweep ...